What’s next in Neuroscience drug discovery

What’s next in Neuroscience drug discovery
hajdola1

/by
Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery
arcticnovartis

  • New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites including Cambridge, Massachusetts, and Basel, Switzerland
  • Approximately 466,000-square-foot site with AI-enabled discovery capabilities, expected to house about 1,000 employees
  • Part of a USD 23 billion US investment to expand R&D and advanced manufacturing to reach more patients

Basel, February 6, 2026 – Novartis today broke grou

/by
Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline

Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline
arcticnovartis

Ad-hoc-Mitteilung gemäss Art. 53 KR

Geschäftsjahr

/by
Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

Full year

/by
How Novartis is helping to eliminate leprosy

How Novartis is helping to eliminate leprosy
imberje1

/by
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis

  • Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1

  • Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care

  • Novartis plans to submit to health authorities globally starting in early 2026
/by
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
arcticnovartis

  • Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1

  • Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement over standard of care

  • Novartis plans to submit to health authorities globally starting in early 2026
/by
Letter to global governments: A call for bold life sciences investment

Letter to global governments: A call for bold life sciences investment
angilma1

/by
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
arcticnovartis

  • New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
  • Purpose-built facility will strengthen Novartis RLT manufacturing network alongside existing Indiana, New Jersey, and recently completed California sites
/by
2/25/2026 : Alcon’s Full-Year 2025 Earnings Call

View the live Webcast

/by